Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25799299 | 0.84 | GABRA1 (0.35) | GABRA1GABRG2GABRB3GABRB2FAAH | |
| SCHEMBL70631 | 0.78 | GABRA1 (0.39) | GABRA1GABRG2GABRB3GABRB2FAAH | |
| SCHEMBL9518260 | 0.76 | — | — | |
| SCHEMBL90913 | 0.76 | ALDH1A1 (0.33) | CA1CA2LMNACYP1A2HPGD | |
| SCHEMBL2735120 | 0.74 | PARP1 (0.47) | GABRA1GABRG2GABRB3GABRB2FAAH | |
| SCHEMBL12824889 | 0.73 | ALDH1A1 (0.39) | GABRA1GABRB2HPGDTSHRHTR2C | |
| SCHEMBL12412399 | 0.72 | TSHR (0.40) | GABRA1CYP1A2HPGDTSHRGABRB1 | |
| SCHEMBL15077055 | 0.72 | ALDH1A1 (0.42) | TSHRCXCR5 | |
| SCHEMBL8373209 | 0.72 | DRD2 (0.39) | CA1CA2LMNACYP3A4HPGD | |
| SCHEMBL7968415 | 0.72 | CXCR5 (0.32) | TSHRCXCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255963-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20210290619-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. | 2021-09-23 | — | — | US | disclosed |
| US-10806733-B2 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190160060-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-05-30 | — | — | US | disclosed |
| US-10034879-B2 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20120277251-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | NEREUS PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277251-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | NEREUS PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8299066-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8247552-B2 | Analogs of dehydrophenylahistins and their therapeutic use | NEREUS PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247552-B2 | Analogs of dehydrophenylahistins and their therapeutic use | NEREUS PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-7919497-B2 | Analogs of dehydrophenylahistins and their therapeutic use | NEREUS PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | Shinonogi & Co., Ltd (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | ASTRAZENECA AB (SE) | 2009-07-16 | — | — | US | disclosed |
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | ASTRAZENECA AB (SE) | 2009-07-16 | — | — | US | disclosed |
| US-20080221122-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE | BEYONDSPRING PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2007035841-A9 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | NEREUS PHARMACEUTICALS INC (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070078138-A1 | Analogs of dehydrophenylahistins and their therapeutic use | BEYONDSPRING PHARMACEUTICALS, INC. | 2007-04-05 | — | — | US | disclosed |
| WO-2007035841-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | NEREUS PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10806733-B2 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | HBB, HBG2, MB | GABRA1 639/4885GABRG2 752/4885GABRB3 328/4885 |
| US-10034879-B2 | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation | HBB, HBG2, MB | GABRA1 639/4885GABRG2 752/4885GABRB3 328/4885 |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | GABRA1 573/4885GABRG2 581/4885GABRB3 303/4885 |
| US-20230255963-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | GABRA1 639/4885GABRG2 752/4885GABRB3 328/4885 |
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNA2, CNR2 | GABRA1 989/4885GABRG2 1740/4885GABRB3 1150/4885 |
| US-20070078138-A1 | Analogs of dehydrophenylahistins and their therapeutic use | MKI67, HPGDS, HCCS | GABRA1 4803/4885GABRG2 4747/4885GABRB3 4609/4885 |
| US-20080221122-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE | HPGDS, DHPS, HCCS | GABRA1 4720/4885GABRG2 4614/4885GABRB3 4666/4885 |
| US-20210290619-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | GABRA1 639/4885GABRG2 752/4885GABRB3 328/4885 |
| US-20120277251-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | MKI67, HPGDS, HCCS | GABRA1 4803/4885GABRG2 4747/4885GABRB3 4609/4885 |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | GABRA1 180/4885GABRG2 300/4885GABRB3 192/4885 |
| US-20190160060-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | GABRA1 639/4885GABRG2 752/4885GABRB3 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.